BRIEF-Astrazeneca Says Lynparza Granted FDA Priority Review For Olympia

 

* ASTRAZENECA PLC - LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA

* ASTRAZENECA - LYNPARZA GRANTED PRIORITY REVIEW IN US FOR BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)